US Patent No: 6,764,998

Number of patents in Portfolio can not be more than 2000

6,11-4C-bicyclic 9a-azalide derivatives

Stats

ATTORNEY / AGENT: (SPONSORED)
 

Importance

Loading Importance Indicators... loading....

Abstract

The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: ##STR1## which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

Loading the Abstract Image... loading....

First Claim

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
ENANTA PHARMACEUTICALS, INC.WATERTOWN, MA111

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Or, Yat Sun Watertown, MA 287 1575
Phan, Ly Tam Quincy, MA 73 287
Wang, Guoqiang Belmont, MA 65 161

Cited Art

Patent Info (Count) # Cites Year
 
AVENTIS PHARMA S.A. (3)
5,444,051 Erythromycin compounds 62 1993
5,527,780 Erythromycin derivatives 53 1993
5,969,161 5-O-deaominyl 6-O-methyl erythronolide a derivatives, method for preparing same and application thereof for preparing biologically active products 21 1998
 
TAISHO PHARMACEUTICAL CO., LTD. (3)
4,990,602 Erythromycin A derivatives 66 1988
5,403,923 6-0-methylerythromycin A derivatives 36 1993
5,631,355 5-O-desosaminylerythronolide a derivatives 30 1994
 
ABBVIE INC. (2)
5,866,549 6-O-substituted ketolides having antibacterial activity 90 1997
6,046,171 6,11-bridged erythromycin derivatives 25 1998
 
ABBOTT LABORATORIES (1)
6,124,269 2-Halo-6-O-substituted ketolide derivatives 50 1998
 
ORTHO-MCNEIL PHARMACEUTICAL, INC. (1)
6,399,582 Ketolide antibacterials 32 2000

Patent Citation Ranking

Forward Cites

Patent Info (Count) # Cites Year
 
ENANTA PHARMACEUTICALS, INC. (14)
7,910,558 Bridged macrocyclic compounds and processes for the preparation thereof 0 2004
7,276,487 9a, 11-3C-bicyclic 9a-azalide derivatives 0 2004
7,414,030 6-11 Bicyclic erythromycin derivatives 4 2005
7,265,094 9N-substituted 6-11 bicyclic erythromycin derivatives 3 2005
7,273,853 6-11 bicyclic ketolide derivatives 12 2005
7,384,921 Polymorphic forms of 6-11 bicyclic ketolide derivatives 4 2005
7,189,704 6-11 bicyclic ketolide derivatives 5 2005
7,402,568 Bicyclic 9a-azalide derivatives 3 2005
7,135,573 Processes for the preparation of O-(6-Pyrazol-1-yl-pyridin-3-ylmethyl)-hydroxylamine 6 2005
7,271,155 9A, 11-2C-bicyclic 9a-azalide derivatives 0 2006
7,563,877 ]oxazol-5-yl)methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182 1 2007
8,273,720 6,11-bicyclolides: bridged biaryl macrolide derivatives 0 2009
8,354,383 6,11-bridged biaryl macrolides 0 2009
8,383,785 Anti-bacterial activity of 9-hydroxy derivatives of 6,11-bicyclolides 0 2009

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 20, 2016
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00